IMPACT OF NEO-ADJUVANT CHEMOTHERAPY IN COLON CANCER

Surgery with adjuvant chemotherapy is currently the gold standard in the management of locally advanced non-metastatic colon cancer. However, a peri-operative strategy is beginning to emerge. The aim of this randomized trial is to report a series of 110 patients operated on for locally advanced non-metastatic colon cancer with evaluation of the impact of neo-adjuvant chemotherapy versus primary surgery in terms of overall survival and recurrence-free survival, with the quality of the complete surgery and histological tumor regression as well as postoperative morbidity and mortality as endpoints. The results show a benefit of neoadjuvant chemotherapy on the quality of surgical excision by down sizing as well as a reduction of major postoperative morbidity and on the anatomopathological results by down staging and partial histological response. There seems to be a superiority of neoadjuvant chemotherapy in terms of median overall survival and recurrence-free survival. This new peri-operative strategy seems to provide tumor control. It would be a kind of pre-enabling for surgery.

Autorentext

Doctor TALBI Nabila, Lecturer class (B), in general surgery, former acting head of the department of oncological surgery and head of women's unit, Center for the fight against cancer in Setif, teacher at the Faculty of Medicine of the University Ferhat Abbas 1 of Setif and member of the Algerian Society of Surgery.